Core Insights - Pharvaris is a biopharmaceutical company focused on developing oral treatments for hereditary angioedema (HAE) using a bradykinin B2 antagonist approach, addressing both on-demand and preventive needs for patients [1][6] Stock Performance - As of December 3, 2025, Pharvaris (PHVS) stock was priced at $29.37, reflecting a 21.75% increase from the previous session, with fluctuations between $23.80 and $29.68 on that day [4] - The stock has experienced a yearly high of $29.67 and a low of $11.51, indicating its volatile nature [4] Market Analysis - Morgan Stanley set a price target of $41 for PHVS, suggesting a potential increase of approximately 39.62% based on the company's promising late-stage pipeline and anticipated phase 3 data by the end of 2025 [2][6] - Pharvaris has a market capitalization of approximately $1.91 billion, indicating a substantial presence in the biopharmaceutical sector [5] Clinical Development - The company has received a buy rating with a target price of $40, driven by strong phase 2 results and regulatory precedents [3][6] - The mechanism of Deucrictibant, a key component of their treatment, has been validated, with an estimated probability of success for the upcoming phase 3 readout exceeding 90% [3]